NeuroLaunch aids ignition for neuscience startups

NeuroLaunch, the first major worldwide program for neuroscience technology businesses, is taking Atlanta by storm in a rolling 90-day program aimed to give participants and their companies the tools needed to succeed, including seed funding, mentorship, and other resources, such as access to top research centers.

“We believe that technological solutions are going to play a large role in treating patients,” NeuroLaunch co-founder and Emory University Neurosurgery resident Jordan Amadio, MD, said in this FOX News report. “But these technologies need to come to market. They can’t remain as ideas in the laboratory without being translated.”

A fall 2014 cohort of start-ups were chosen Oct. 1. Applications are currently being taken for another cohort that will be chosen at an unspecified time for the summer 2015 program.

Around the web

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?